CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...
Phase 2
Barcelona, Spain and 80 other locations
and tolerability of these combinations in adult participants with glioblastoma (GBM).The primary purpose of Phase 2 of this study is...
Phase 1, Phase 2
Barcelona, Spain and 9 other locations
as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma...
Phase 1
Barcelona, Spain and 11 other locations
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change)....
Phase 3
Barcelona, Spain and 122 other locations
The purpose of this first-in-human (FIH) study of [177Lu]-NeoB is to characterize the safety, tolerability, pharmacokinetics (PK) as well as the dist...
Phase 1, Phase 2
Barcelona, Spain and 13 other locations
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma...
Phase 1
Barcelona, Catalunya, Spain and 12 other locations
(TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic can...
Phase 2
Barcelona, Spain and 87 other locations
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors th...
Phase 1
Hospitalet de LLobregat, Catalunya, Spain and 4 other locations
used as adjuvant treatment in patients with newly diagnosed GBM who are MGMT unmethylated and have completed concomitant treatment with temo...
Early Phase 1
Barcelona, Spain and 4 other locations
progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of i...
Phase 3
Barcelona, Spain and 18 other locations
Clinical trials
Research sites
Resources
Legal